Therapeutics

Amyloid-Related

  • Study completed / Planned end date
  • Planned end date unavailable
  • Study aborted
Amyloid-Related 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
AGB101
Phase 2
ALZT-OP1
Phase 3
AN-1792
Phase 2
AZD3293
Phase 2/3
Acitretin
Phase 2
Aducanumab
Phase 3
Affitope AD02
Phase 2
Avagacestat
Phase 2
Azeliragon
Phase 3
BAN2401
Phase 1, Phase 2
Bapineuzumab
Phase 2, Phase 3
CAD106
Phase 2
CHF 5074
Phase 2
CNP520
Phase 2, Phase 2/3
Crenezumab
Phase 2, Phase 3
E2609
Phase 2
ELND005
Phase 2
EVP-0962
Phase 2
Gamunex
Phase 2/3
Gantenerumab
Phase 2/3, Phase 3
JNJ-54861911
Phase 2, Phase 2/3
NIC5-15
Phase 2
Octagam®10%
Phase 2
Ponezumab
Phase 2
Solanezumab
Phase 2, Phase 2/3, Phase 3
Thalidomide
Phase 2/3
Vanutide cridificar
Phase 2
Verubecestat
Phase 1, Phase 2/3, Phase 3